Title |
Long-term costs of introducing HPV-DNA post-treatment surveillance to national cervical cancer screening in Ireland
|
---|---|
Published in |
Expert Review of Pharmacoeconomics and Outcomes Research, September 2015
|
DOI | 10.1586/14737167.2015.1057126 |
Pubmed ID | |
Authors |
Maria Agapova, Andrea Duignan, Alan Smith, Ciaran O’Neill, Anirban Basu |
Abstract |
Co-testing (cytology plus human papillomavirus DNA testing) as part of cervical cancer surveillance in Ireland increases one-time testing costs. Of interest to policy makers was the long-term impact of these costs accompanied by decreases in intensity of recalls for women with no detected abnormalities. A cost analysis of cytology-only and co-testing strategy was implemented using decision analytic modeling, aggregating testing utilization and costs for each of the two strategies over 12 years. Aggregated incremental costs of the co-testing strategy were positive for the first 3 years but became negative thereafter, generating a cost savings of roughly €20 million in favor of the cytology-only strategy over a 12-year period. Results were robust over a range of sensitivity analyses with respect to discount and attrition rates. This analysis provided valuable information to policy makers contributing to the introduction of co-testing for post-treatment surveillance (PTS) in Ireland. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 3% |
Unknown | 32 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 7 | 21% |
Researcher | 3 | 9% |
Student > Ph. D. Student | 3 | 9% |
Other | 2 | 6% |
Student > Doctoral Student | 2 | 6% |
Other | 5 | 15% |
Unknown | 11 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 30% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 9% |
Social Sciences | 2 | 6% |
Mathematics | 1 | 3% |
Agricultural and Biological Sciences | 1 | 3% |
Other | 5 | 15% |
Unknown | 11 | 33% |